Loading clinical trials...

The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome | Clinical Trials | Clareo Health

RECRUITING

The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome

The Epidemiological Patterns of Obstructive Sleep Apnea Syndrome in Patients With Chronic Kidney Disease and Its Impact on Renal Prognosis

NCT06971874•Nanfang Hospital, Southern Medical University

View on ClinicalTrials.gov

Summary

Obstructive sleep apnea (OSA) is highly prevalent in chronic kidney disease (CKD) patients and strongly linked to obesity, metabolic syndrome, and type 2 diabetes. Besides elevating cardiovascular disease risk, OSA may worsen renal function and diminish quality of life, making its understanding critical for CKD patient health. This study will establish a large, long-term cohort of non-dialysis CKD patients to identify OSA risk factors, explore OSA's association with adverse renal outcomes, and determine OSA prevalence and epidemiological characteristics within the CKD population. The findings will provide a scientific foundation for early OSA identification, diagnosis, and intervention in CKD patients.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Voluntarily sign the informed consent form;
•* Aged ≥ 18 years and \< 75 years;
•* Patients with CKD stages 3-4, with an eGFR of 15-60 ml/min/1.73m² calculated using the CKD-EPI formula for at least 3 months.

Exclusion Criteria

•Patients receiving oxygen therapy or continuous positive airway pressure (CPAP) treatment;
•* Patients with other sleep disorders, including restless legs syndrome, periodic limb movement disorder, etc.;
•* Patients with other severe comorbidities: Severe heart failure (NYHA class III or IV); Myocardial infarction, unstable angina, or stroke within the past 3 months; Severe arrhythmias requiring medication or device therapy; Respiratory diseases, including COPD, asthma, thoracic deformities, etc.; Neurological disorders, including myasthenia gravis, Parkinson's disease, Alzheimer's disease, etc.; Active liver disease or severe hepatic insufficiency; Psychiatric conditions, including depression, anxiety disorders, etc.; History of malignancy within the past 5 years (except cured basal cell carcinoma); Uncontrolled hyperthyroidism;
•* Patients who underwent surgery or had acute infections within the past 3 months;
•* Current heavy alcohol consumption:Females: \>3 drinks/day or \>7 drinks/week; Males: \>4 drinks/day or \>14 drinks/week (1 standard drink = 14g of alcohol)
•* Current use of medications that may severely interfere with sleep, such as antipsychotics, antiepileptics, antiparkinsonian drugs, antidepressants, opioids, etc.;
•* Females who are pregnant or lactating at screening or baseline;
•* Inability to comply with the study due to: Low education level, language barriers, inability to tolerate or complete sleep monitoring, or other reasons preventing completion of study procedures (e.g., follow-up);
•* Deemed unsuitable for participation by the investigator's judgment.

Locations (1)

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China

Key Dates

Start Date

July 17, 2025

Primary Completion Date

June 30, 2029

Completion Date

December 31, 2029

Last Updated

November 17, 2025

Enrollment

356

ESTIMATED participants

Conditions

Chronic Kidney DiseasesOSAS (Obstructive Sleep Apneas Syndrome)

Interventions

No intervention

OTHER

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

NCT04592640

Chronic Kidney DiseasesCalciphylaxis+4 more

View study

RECRUITINGNA

Handgrip Exercise Training and CKD

NCT07094906

Chronic Kidney Diseases

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome

Inclusion Criteria

Exclusion Criteria

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

Handgrip Exercise Training and CKD

Eye-Brain-Kidney in CKD

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect